Company intelligence / Profile preview

Orthomol

Langenfeld, North Rhine-Westphalia, Germanyorthomol.com ↗

Ownership: Private
Employees: ~400
Development stage: Commercial

Overview

No traditional clinical trial pipeline. Products are supported by scientific literature reviews and internal research into micronutrients' roles in human physiology. Some individual ingredients may have published studies supporting their use.

Therapeutic areas: EndocrinologyCardiovascularImmunology
Modalities: Nutritional supplement (Micronutrient combinations)Probiotic (in some products)Vitamin and mineral blendsAmino acid blend (in some products)Phytonutrient blend (in some products)
Industry: Food & Nutrition

Drug pipeline

2 assets

Orthomol Immun

Commercial

Indications: Immune deficiency

1 more asset in the full pipeline.

Request access →

Partnerships

Dong-A Pharmaceutical (exclusive distribution partner in South Korea)

Beyond the preview

Go deeper on Orthomol.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orthomol.

Explore the full profile